Skip to main content

Table 2 Analyses for prognostic indicators of Overall Survival

From: Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

Variable Overall Survival
Univariate analysis Multivariate analysis
P Value HR P Value HR
Age at diagnosis (years)
 ≤70 vs >70
0.035 5.812 0.174 ――
Gland volume (mL)
 ≤33 vs >33
0.006 3.816 0.042 1.192
MAB
 Continuous vs Intermittent
0.583 ―― 0.457 ――
PPB
 yes vs no
0.007 3.016 <0.001 6.358
Clinical stage
 ≤ T2c vs ≥T3a
<0.001 4.557 0.011 2.183
Gleason score
 ≤7 vs ≥8
0.001 3.356 <0.001 7.142
PSA at diagnosis (ng/mL)
 ≤10 vs 10~20 vs ≥20
0.027 1.558 0.014 3.492
Memorial Sloan-Kettering risk classification
 2~3 IS vs 1 HS vs 2 HS
<0.001 7.658 <0.001 5.479
PSA nadir (ng/mL)
 ≤1 vs >1
<0.001 9.473 0.012 4.553
Time to PSA nadir (months)
 ≤3 vs >3
0.012 3.113 0.038 1.249
PSA doubling time (months)
 ≤12 vs >12
0.042 2.665 0.028 5.511
PSA decrease (%)
 <90 vs ≥90
<0.001 13.463 <0.001 7.845
  1. MAB Maximal Androgen Blockade; PPB Permanent Prostate Brachytherapy; IS intermediate-Risk Standard; HS High-Risk Standard